Jeffrey L. Port, M.D.

Jeffrey L. Port, M.D.

Chairman & Co-Founder

Dr. Port is a Professor of Cardiothoracic Surgery and an Attending Surgeon in the Division of Thoracic Surgery at New York Presbyterian-Weill Cornell Medical Center within the Department of Cardiothoracic Surgery. Dr. Port earned his medical school degree and also finished his general surgery residency at the New York University School of Medicine. He then completed his cardiothoracic surgical training at Weill Cornell Medical Center and Memorial Sloan Kettering Cancer Center where he developed an interest in thoracic oncology, specifically in lung and esophageal cancer. As an Attending Thoracic Surgeon at Weill Cornell Medical Center, Dr. Port specializes in lung and esophageal cancers, mediastinal tumors and Barrett’s Esophagus. He also specializes in the area of minimally invasive thorascopic pulmonary surgery and the treatment of emphysema patients who require lung volume reduction. Dr. Port has authored numerous journals and book chapters on immunotherapy for the treatment of lung and esophageal cancer, as well as the development of vaccines. Dr. Port has an ongoing research collaboration with Dr. Rafii in the area of tumor endothelium and lung regeneration. He is a member of the American College of Surgeons, American Society of Clinical Oncology, American Association for Cancer Research, American Association of Thoracic Surgery, and Society for Thoracic Surgeons. Dr. Port is Board Certified in Surgery and Thoracic Surgery. He is also the founder of RF Surgical Systems, Inc., a medical device company with headquarters in Bellevue, Washington and engineering R & D facilities in San Diego, California. Today, RF Surgical Systems is the market leader in retained surgical sponge detection.

Andrew Brooks, Ph.D.

Andrew I. Brooks, Ph.D.

Director

Andrew is the Chief Operating Officer of RUCDR Infinite Biologics (RUCDR) at Rutgers University, the world’s largest academic biorepository managing critical biological resources for clients such as The National Institute of Health, leading academic researchers, and major pharmaceutical and biotechnology companies. Additionally, Andrew is the Chief Scientist for Brooks Life Sciences, a division of the $2 billion (NASDAQ) Brooks Corporation.

Andrew is a Professor of Medicine and Genetics at Rutgers University. He is trained in molecular neuroscience and gene therapy and is widely recognized as a thought leader in the field of personalized medicine. And he has deep experience in advising leading US, global institutions, and governments on health policy, including serving on the boards and scientific leadership of several global biorepository and precision medicine programs in Europe, Qatar, and Australia.

Paul Finnegan, M.D., M.B.A.

Paul Finnegan, M.D., M.B.A.

Chief Executive Officer

Dr. Finnegan is Chief Executive Officer of Angiocrine Bioscience. He has more than 20 years of life science management experience in the biotechnology, pharmaceutical, and healthcare industries – including extensive operational and strategic leadership roles in venture-backed start-ups and multi-billion dollar publically listed global companies, complemented by service on boards of both private and public biotechnology companies. Most recently, Dr. Finnegan has been advising boards and senior management of emerging biotechnology and pharmaceutical companies on strategic, commercial, business development, clinical, and regulatory matters, including companies focused on cellular immunotherapy (for cancer) and cellular regenerative therapies. From 2012-2014, Dr. Finnegan served as Vice President and General Manager, Asia-Pacific for ViroPharma, Inc., which was acquired by Shire PLC for $4.2 billion. In this role, he initiated ViroPharma’s business in the Asia-Pacific region, and launched and developed Cinryze® and commercialized Plenadren®. Dr. Finnegan concurrently served as Director (Board) of Imprimis Pharmaceuticals (2012-2013) and on the Audit, Compensation, and Nomination & Governance Committees. From 2008-2011, Dr. Finnegan was retained exclusively to manage start-ups wholly funded by Avalon Ventures, where he was CEO of Avelas BioSciences and InCode Biotherapeutics, participated as board observer for various Avalon portfolio companies, and provided commercial, clinical and regulatory due diligence for new Avalon Fund investments. From 2007-2008, Dr. Finnegan served as founding CEO of Cecoura Therapeutics, a start-up wholly owned by Paramount BioSciences. From 2001-2007, Dr. Finnegan served as Vice President of Commercial Operations and Development, and then later as Vice President of Global Strategic Marketing for Alexion Pharmaceuticals, Inc. While at Alexion, Dr. Finnegan co-founded the paroxysmal nocturnal hemoglobinuria clinical program for eculizumab, built the first commercial organization, and initiated and led the global commercialization of Soliris® – the most successful ultra-orphan product launch in 2007. From 1998-2000, Dr. Finnegan was Senior Director, Global Medical Marketing, APLAC Region for Searle, a division of Monsanto and then of Pharmacia Corp in 2000. While at Searle, Dr. Finnegan played key roles in his market region for the launch of Celebrex® – the most successful pharmaceutical product launch in 1999. Prior to Searle, Dr. Finnegan was a fellowship-trained interventional radiologist and an entrepreneur in the healthcare provider segment. Dr. Finnegan earned his M.D., C.M. from McGill University, Montreal, Canada, and his M.B.A. in Finance and Strategy from the University of Chicago, Booth Graduate School of Business and is a Fellow of the Royal College of Physicians, Canada (FRCPC) and a Member of the American Society of Hematology (ASH).

Jeff Jonas

Jeff Jonas, M.D.

Director

Jeff Jonas is CEO of Sage Therapeutics, bringing with him more than 25 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, with a focus on central nervous system disorders. At Sage, he’s created an engine of innovation that encourages creating new opportunities by taking smart risks and challenging conventional wisdom. Jeff’s approach is shaped by a career that encompasses one-on-one patient care, rapid advancement through corporate structures, academic accomplishments, and entrepreneurial endeavors. Before joining the Sage team, Jeff served as President of the Regenerative Medicine Division of Shire plc and previously as Senior Vice President of Research and Development, Pharmaceuticals at Shire. Prior to Shire, he served as the Executive Vice President of ISIS Pharmaceuticals, as the Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and in senior-level positions at Upjohn Laboratories. Jeff is a member of the board for Generation Bio and Karuna Pharmaceuticals. He has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts and has received numerous awards.

Jeff received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard and then served as Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School.

David R. Parkinson, MD

David R. Parkinson, M.D.

Director

Dr. Parkinson has served as President and Chief Executive Officer of ESSA Pharma Inc. since January 2016, and as a Director of the company since June 2015. Prior to joining ESSA he had been a Venture Partner at New Enterprise Associates, Inc. From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, Inc., a biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy. Until October 2007 he was SVP, Oncology Research and Development at Biogen Idec, where he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously he had served as VP, Oncology Development, at Amgen and VP, Global Clinical Oncology Development, at Novartis. In those roles he oversaw the successful clinical development of a series of cancer therapeutics, including Gleevec, Zometa, Femara, and Vectibix. Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch and then as Acting Associate Director of the Cancer Therapy Evaluation Program (CTEP). He is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee, a past member of the FDA Science Board, and is a recipient of the FDA’s Cody Medal. He is a past editor of the Journal of Immunotherapy and past president of the Society of Biological Therapy. He has served on the National Cancer Policy Forum of the Institute of Medicine and is a past co-chair of the Cancer Steering Committee of the NIH Foundation Biomarkers Consortium. A past Board Director of the Ontario Institute for Cancer Research, he currently serves as a Board Director for the Multiple Myeloma Research Foundation. He served as Chairperson of the American Association of Cancer Research (AACR) Finance and Audit Committee for 15 years and is a previous elected Board Director of AACR. Dr. Parkinson was a Director of Facet Biotech, Inc., until the acquisition by Abbott Pharmaceuticals, and was a Director of Ambit Biosciences until the acquisition by Daiichi Sankyo. He was also previously a Director at Threshold Pharmaceuticals, Cerulean Pharmaceuticals and Tocagen, Inc (TOCA). He currently serves as Director on the Boards of 3SBio Inc (1530.HK), CTI Biopharma, Inc (CTIC), and is a Co-Founder and Director of Refuge Biotech, Inc. He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center, and has authored over 100 peer-reviewed publications.